| Literature DB >> 26925137 |
Qiaoshi Zhao1, Yuzhi Yang2, Jing Hu1, Zhiyan Shan1, Yanshuang Wu1, Lei Lei1.
Abstract
INTRODUCTION: Stem cells involved cell replacement therapies for type 1 diabetes mellitus is promising, yet time-consuming and inefficient. Exendin-4 is a glucagon-like peptide-1 (GLP-1) receptor agonist which has been reported to possess anti-apoptotic effects, thereby increasing β-cell mass and improving β-cell function. The present study aimed to investigate whether exendin-4 would enhance the differentiation of embryonic stem cells into insulin-secreting cells and improve the pancreatic differentiation strategy.Entities:
Keywords: diabetes; embryonic stem cells; exendin-4; insulin-producing cell
Year: 2016 PMID: 26925137 PMCID: PMC4754381 DOI: 10.5114/aoms.2016.57596
Source DB: PubMed Journal: Arch Med Sci ISSN: 1734-1922 Impact factor: 3.318
Figure 1Scheme of the differentiation protocol
Sequences of primers, annealing temperatures and product sizes
| Gene | Primer sequence | Annealing temperature [°C] | Product size [bp] |
|---|---|---|---|
| Isl1 | Forward: 5’ GTTTGTACGGGATCAAATGC 3’ | 56 | 503 |
| Reverse: 5’ ATGCTGCGTTTCTTGTCCTT 3’ | |||
| Pdx1 | Forward: 5’ CCACCCCAGTTTACAAGCTC 3’ | 56 | 315 |
| Reverse: 5’ ACGGGTCCTCTTGTTTTCCT 3’ | |||
| Ngn3 | Forward: 5’ TGGCGCCTCATCCCTTGGATG 3’ | 54 | 245 |
| Reverse: 5’ TCTTCGCTGTTTGCTGAGTG 3’ | |||
| Insulin1 | Forward: 5’ TAGTGACCAGCTATAATCAGAGAC 3’ | 56 | 288 |
| Reverse: 5’ CGCCAAGGTCTGAAGGTC 3’ | |||
| Neurod1 | Forward: 5’ CTTGAAGCCATGAATGCAGA 3’ | 56 | 388 |
| Reverse: 5’ GCGTCTGTACGAAGGAGACC 3’ | |||
| Glut2 | Forward: 5’ TTCGGCTATGACATCGGTGTG 3’ | 56 | 556 |
| Reverse: 5’ AGCTGAGGCCAGCAATCTGAC 3’ | |||
| Gapdh | Forward: 5’ TGAAGGTCGGTGTGAACGGAT 3’ | 54 | 470 |
| Reverse: 5’ CAGGGGGGCTAAGCAGTTGGT 3’ |
Isl1 – ISL1 transcription factor, Pdx1 – pancreatic and duodenal homeobox gene 1, Ngn3 – neurogenin 3, Neurod1 – neurogenic differentiation 1, Glut2 – glucose transporter 2, Gapdh – glyceraldehyde-3-phosphate dehydrogenase.
Figure 2Morphology of RI ES cells, insulin-producing cells derived from different differentiation protocols. A – Morphology of R1 ES cells. B – Alkaline phosphatase (AP) staining of R1 ES cells. C – In vitro formation of simple EBs on day 6 of stage 1. D–F – Insulin-producing cells derived from different differentiation protocols. D – low dosage group, E – high dosage group, F – control group. Scale bars = 25 µm
Figure 3Gene expression profiles of endocrine and late stage pancreas markers in stage 3 cells. Gene expression was assessed at D14 (A), D21 (B), and D31 (C) of differentiation progress. D – Relative mRNA expression of specific genes involved in pancreas development. RT-PCR was performed in triplicate and the data represent mean ± SD
L – low dosage group, H – high dosage group, C – control group. aP < 0.05 compared to control group, bp < 0.05 compared to low dosage group.
Figure 4Immunostaining of insulin and C-peptide. Day 31 R1 ES cell-derived insulin-producing cells were immunostained with antibodies against insulin (A) and C-peptide (B). A – Positive signals for insulin were easily observed in groups C, L and H. B – C-peptide positive staining was observed only in groups H and L. Nuclei were stained with DAPI (4’,6-diamidine-2’-phenylindole dihydrochloride). Scale bars = 25 µm